Femasys Inc. reported Q3 2024 revenue of $554,908, up 127% YoY, driven by initial commercial sales of FemaSeed infertility treatment and increased FemVue sales. The quarter marked the first U.S. and international sales of FemaSeed following FDA clearance in September 2023, with strategic distribution partnerships established in Spain expected to generate over $1.3 million in the next year.Operating expenses increased 29.3% to $5.48 million, primarily due to a $1.5 million rise in sales and marketing costs as the company built out its commercial team. R&D expenses grew 11.1% to $2.3 million focused on advancing the FemBloc permanent birth control pivotal trial. Net loss widened to $5.41 million from $4.0 million last year.The company ended Q3 with $7.61 million in cash and cash equivalents, which management expects will fund operations into July 2025. However, Femasys indicated substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is exploring various funding options while advancing commercialization of FemaSeed and clinical development of FemBloc.

Femasys Inc. reported Q3 2024 revenue of $554,908, up 127% YoY, driven by initial commercial sales of FemaSeed infertility treatment and increased FemVue sales. The quarter marked the first U.S. and international sales of FemaSeed following FDA clearance in September 2023, with strategic distribution partnerships established in Spain expected to generate over $1.3 million in the next year.Operating expenses increased 29.3% to $5.48 million, primarily due to a $1.5 million rise in sales and marketing costs as the company built out its commercial team. R&D expenses grew 11.1% to $2.3 million focused on advancing the FemBloc permanent birth control pivotal trial. Net loss widened to $5.41 million from $4.0 million last year.The company ended Q3 with $7.61 million in cash and cash equivalents, which management expects will fund operations into July 2025. However, Femasys indicated substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is exploring various funding options while advancing commercialization of FemaSeed and clinical development of FemBloc.